← SynDRA
AVACOPAN
SynDRA canonical compound SYN0039104 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | C5AR1 | C5AR2 |
|---|
| Mechanism of action | complement inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- C5AR1 ANTAGONIST
- C5a anaphylatoxin chemotactic receptor antagonist
- complement inhibitor
Drug classes
- Cytochrome P450 3A4 Inhibitors
- Complement 5a Receptor Antagonist
- Complement 5a Receptor Antagonists
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- tavneos
- CCX168
- AVACOPAN (CCX168)
- CCX-168
- Tavneos
- O880NM097T
- avacopanum
- RefChem:57020
- DTXCID701534346
- Avacopan [INN]
- Avacopan [USAN]
- Avacopan (CCX168)
- Avacopan [USAN:INN]
- UNII-O880NM097T
- MFCD28502293
- Avacopan?
- C33H35F4N3O2
- Tavneos (TN)
- Avacopan (Standard)
- CCX168; Avacopan
- AVACOPAN [JAN]
- AVACOPAN [WHO-DD]
- Avacopan (JAN/USAN/INN)
- AVACOPAN [ORANGE BOOK]
- GTPL9450
- orb1299109
- SCHEMBL2567144
- SCHEMBL29644823
- SCHEMBL29707926
- EX-A2605
- HY-17627R
- AKOS040759342
- CS-6888
- EBC-171025
- AC-35654
- DA-61333
- HY-17627
- SY312786
Reported adverse events
- Angioedema
- Headache
- Hepatotoxicity
- Hypersensitivity
- Nausea
- Vomiting
- Infection
- Blood creatinine increased
- Dizziness
- Fatigue
- Hepatitis B
- Hypertension
Look up AVACOPAN in the interactive SynDRA portal →